Intech Biopharm Corporation (6461.TWO)

TWD 26.4

(-1.31%)

Market Cap (In TWD)

3.64 Billion

Revenue (In TWD)

25.84 Million

Net Income (In TWD)

-337.98 Million

Avg. Volume

334.04 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
23.6-34.6
PE
-
EPS
-
Beta Value
0.328
ISIN
TW0006461007
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Wei-Shiu Wu
Employee Count
-
Website
https://www.intechbiopharm.com
Ipo Date
2014-07-15
Details
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.